Opened 1075 days ago
Closes 31 December 2023
Trial Aim Description
Testing a potential new treatment/investigational product for (Inclusion Body Myositis) IBM. The potential new treatment/investigational product is called Sirolimus.
Trial Eligibility Requirements
Patients must have a confirmed diagnosis of IBM and be aged 45 years or older.
Interested? Enquire today
Principal Investigator: Professor Merrilee Needham
Enquiries Email: k.beer@iiid.murdoch.edu.au